European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. pocket expenses account for only seven percent of the overall cost of developing drugs.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

European Pharmaceutical Review

DECEMBER 21, 2022

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. Gene Ther 27, 537–544 (2020). Science 369, eabc3183 (2020).

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

pharmaphorum

JANUARY 9, 2023

Novartis paused development across all its potential indications three years later, citing more pressing priorities in its pipeline – so, Stalicla’s licensing deal has resurrected a dormant programme. The market potential of the CUD and NDD indications alone could top 2 billion euros ($2.12 billion) globally, the company noted.

Compounding 59

Compounding Drug Development 59

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. BMB Reports. 2017;50(3):111–6. Premier Consulting [Internet].

Drug Development 103

Drug Development Biosimilars Documentation Labelling 103

pharmaphorum

MAY 13, 2021

The new project comes shortly after Exscientia and its development partner Evotec began human trials of cancer immunotherapy EXS-21546 in advanced solid tumours. In January 2020, DSP also started dosing patients in a study of DSP-1181 , a drug for obsessive-compulsive disorder billed as the first AI-designed drug to enter the clinic.

Compounding 55

Compounding Drug Development 55

Pulses

AUGUST 31, 2023

doi:10.1108/IJILT-06-2020-0108 Reiners D, Davahli MR, Karwowski W, Cruz-Neira C. Onime C, Uhomoibhi J, Wang H, Santachiara M. A reclassification of markers for mixed reality environments. Campus-wide information systems. 2021;38(1):161-173. The combination of Artificial Intelligence and Extended Reality: A Systematic Review. 2021;2:721933.

Medication Dispensing 78

Medication Dispensing Medication Labelling Packaging Labelling 78

European Pharmaceutical Review

OCTOBER 9, 2022

Research published in the journal Nature Chemistry , shows how researchers from Stanford University in the US uncovered a promising new method to synthetically manufacture the compound tigilanol tiglate, named EBC-46, which could offer targeted medicine for cancer and other diseases.

Compounding 144

Compounding Drug Development 144

Express Pharma

AUGUST 2, 2023

Centhaquine, a first-in-class drug developed by Pharmazz India, a majority-owned subsidiary of Pharmazz, has received approval from the US-FDA to enter phase 3 clinical trials in the US and the EU. Pharmazz India obtained marketing authorisation for Lyfaquin (INN: Centhaquine) to manage hypovolemic shock in India in May 2020.

Compounding 94

Compounding Hospitals Drug Development 94

European Pharmaceutical Review

JANUARY 29, 2024

17 Accelerating drug development The first issue of 2023 , 18 dealt with accelerating drug development. The FDA, in its “Overview of Major Quality Deficiencies and Approaches Available in GDUFA III” (generic drug user fee amendments) identified dissolution testing as one of its major quality deficiencies during 2023.

Drug Development 111

Drug Development Vaccines Compounding 111

Pharmaceutical Technology

JULY 23, 2008

Despite the enormous growth being enjoyed by the global oncology market, potential cancer cures are left on laboratory shelves on a regular basis, according to Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office. “Companies shelve research on a regular basis,” she says.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Compounding Biosimilars 40

European Pharmaceutical Review

FEBRUARY 14, 2024

As previously highlighted batch-to-batch variability in potency is expected, however, the compounding effect of method related variability in quantification makes root cause analysis even more difficult when trying to identify those parameters/conditions for process establishment/scale up. 2020; 144:104160 3. cited 2023Nov].

Dosage 97

Dosage Packaging Labelling Compounding 97

Pharmaceutical Technology

MARCH 22, 2023

According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. This was higher than the number of approvals in 2019 and 2020. Several drug development trends are driving injectables demand.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

JANUARY 16, 2023

MALDI-TOF works on the basis of the ionisation of chemical compounds and measurements of their mass to charge (m/z) ratio. Prior to November 2013 he worked for Merck Research Laboratories in Summit, New Jersey as the Senior Principal Scientist in early phase drug development.

Vaccines 128

Vaccines Research Laboratories Documentation Compounding 128